Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH TALAZOPARIB IN PATIENTS WITH BRCA OR ATM MUTANT TUMORS JAVELIN BRCA/ATM

NCT03565991 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03565991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03565991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH TALAZOPARIB IN PATIENTS WITH BRCA OR ATM MUTANT TUMORS JAVELIN BRCA/ATM
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
June 18, 2018
Completion date
February 3, 2023
Enrollment
202 (actual)
Sites
100

Conditions

As the registry lists them; a condition with its own page is linked.

genes, brca 1, locally advanced or metastatic solid tumors